S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Bitcoin Rockets To Record High But Buy THIS Instead (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
NASDAQ:KERX

Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis

→ Your Money is Not Safe (From American Alternative) (Ad)
Free KERX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.97
▼
$3.47
50-Day Range
N/A
52-Week Range
$2.47
▼
$5.98
Volume
2.60 million shs
Average Volume
1.69 million shs
Market Capitalization
$344.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
KERX stock logo

About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

KERX Stock News Headlines

April 13, 2024 | morningstar.com
Caliway Biopharmaceuticals Co Ltd 6919
November 15, 2023 | morningstar.com
XTL Biopharmaceuticals Ltd ADR XTLB
April 19, 2024 | Altimetry (Ad)
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
September 11, 2023 | investing.com
ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)
August 13, 2023 | finance.yahoo.com
Q2 2023 Westrock Coffee Co Earnings Call
July 29, 2023 | thestreet.com
Keryx CEO vs. a Short-Seller: Zerenex Patent Debate
May 12, 2023 | marketwatch.com
8-K: CUTERA INC
May 6, 2023 | seekingalpha.com
Manoj Madhavan
April 19, 2024 | Altimetry (Ad)
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
May 3, 2023 | finance.yahoo.com
Biopharmaceuticals Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand and Forecast
April 13, 2023 | wsj.com
Staidson (Beijing) Biopharmaceuticals Co. Ltd.
March 28, 2023 | finance.yahoo.com
Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners
January 29, 2023 | marketwatch.com
Biopharmaceuticals Market 2023 Analysis by Market Size, New Technology, Growth Rate, Geographical Regions, Drivers and Outlook to 2027
January 25, 2023 | seekingalpha.com
NAVB Navidea Biopharmaceuticals, Inc.
January 25, 2023 | finance.yahoo.com
Biopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)
September 15, 2022 | thestreet.com
Well-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug Launch
October 26, 2021 | finance.yahoo.com
Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
July 29, 2021 | au.finance.yahoo.com
Twitter tests notification banner for suspended and locked accounts
July 29, 2021 | yahoo.com
Joey Jordison, Slipknot co-founder and longtime drummer, dies at age 46
July 28, 2021 | uk.finance.yahoo.com
Why Starbucks (SBUX) Might Surprise This Earnings Season
July 27, 2021 | uk.finance.yahoo.com
UN: World leaders can attend annual UN meeting in person
July 27, 2021 | nz.finance.yahoo.com
Creekstone Farms Meats Sizzle on Yoder Smokers With New Partnership
July 27, 2021 | au.finance.yahoo.com
Midtown, Atlanta Based Innovien Solutions Continues Growth Streak
July 27, 2021 | nz.finance.yahoo.com
Jill Biden Made This Versatile Bag Sell Out, and She Just Wore It Again
July 27, 2021 | yahoo.com
It's Your Business | More improvements on tap for Target on North Prospect
See More Headlines
Receive KERX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KERX
CUSIP
49251510
CIK
1114220
Web
www.keryx.com
Phone
617-466-3500
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-163,440,000.00
Net Margins
-96.41%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-60.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$60.64 million
Price / Sales
5.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-28.00

Miscellaneous

Outstanding Shares
102,380,000
Free Float
N/A
Market Cap
$344.00 million
Optionable
Optionable
Beta
2.35
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Ms. Jodie Pope Morrison (Age 43)
    Interim CEO & Director
  • Mr. Scott A. Holmes (Age 44)
    CFO, Sr. VP & Treasurer
  • Ms. Christine A. Carberry (Age 57)
    Sr. VP & COO
  • Dr. John F. Neylan (Age 65)
    Sr. VP & Chief Medical Officer
  • Mr. Tony Chambers
    VP of Sales

Key Competitors

View All Competitors

KERX Stock Analysis - Frequently Asked Questions

How were Keryx Biopharmaceuticals' earnings last quarter?

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analysts' expectations of $29.56 million.

What other stocks do shareholders of Keryx Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Akebia Therapeutics (AKBA), Ariad Pharmaceuticals (ARIA), Chesapeake Energy (CHKAQ) and Celldex Therapeutics (CLDX).

This page (NASDAQ:KERX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends